We want every man with prostate cancer – or at risk of it – to have access to the same high-quality diagnosis, treatment and support, no matter where in the UK he lives. In a complex and pressured health service, we know clinicians are the key to driving improvement.
This programme is for those working along the prostate cancer pathway to develop their skills and knowledge to drive improvements in advanced metastatic prostate cancer care and support.
If you have specific queries about the Improvement Programmes, please email firstname.lastname@example.org.
CLOSED we are no longer accepting applications
All programmes will be designed to work in parallel with a busy clinical schedule and are carefully planned to deliver maximum value in a minimum time span.
Module 1: Monday 24 and Tuesday 25 February 2020 (residential)
Module 2: Monday 20 April 2020
Please ensure you can attend all 3 days prior to application.
Registration will open at 10.00am on Monday 24 February and the day will be followed by a drinks reception and dinner. The programme will resume at 8.30am Tuesday 25 February and will conclude at 1pm.
On Monday 20 April the programme will commence at 10.30 am and conclude at 4pm.
Central London, venue to be confirmed.
Accommodation and travel
If required accommodation will be provided near the venue for the night of Monday 24 February 2020. Please note travel expenses are not reimbursable.
The aim of this programme is to address some of the challenges around advanced metastatic prostate cancer, develop key skills and knowledge critical to driving improvement and develop a mutually supportive network of improvement leaders.
This programme will focus on developing leaders of improvement through:
- Leadership and change management theory
- Opportunity to put this theory into practice
- Peer learning
- Coaching and support
- Networking with existing inspirational leaders
- Support to develop an improvement plan
The Prostate Cancer Improvement Programmes have been supported by grants from BTG, now part of Boston Scientific, Bayer UK and Sanofi Genzyme. None of these organisations have had any control over the educational content of this activity.